



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: David A Saunders

Art Unit: 1644

re Application of
Gehrmann et al.

Application No.: 08/989,896

Filed: December 12, 1997

Title: Fusion Proteins For Prodrug Activation

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450, on

August 24, 2005

Date of Deposit

Denise Walker

Signature

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER
READABLE COPIES AND REFERENCE TO ANOTHER APPLICATION
ON FILE PURSUANT TO 37 C.F.R. 1.821 (e) AND (f)

Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

In compliance with 37 C.F.R. 1.821(e), applicants would like to request transfer of the computer readable form filed in application Serial No. 08/475,826 filed on June 7, 1995, of which the application filed herewith has been designated as a continuation. A substitute computer readable form was filed in application Serial No. 08/475,826 on September 27, 1996.

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821(c), and the computer readable copies required by 37 C.F.R. 1.821 (e), which has above been requested to be transferred from application Serial No. 08/475,826, filed on September 27, 1996, are the same.

Respectfully submitted,

Ann Marie Szczepanik, Reg. No. 52,267

Attorney/Agent for Applicant

sanofi-aventis
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4757
Telefax (908) 231-2626
Aventis Docket No. DEAV1992/B024 US CNT2